In critical illness the regulation of inflammation and oxidative stress can improve patient outcomes, and thus omega-3 polyunsaturated fatty acids (PUFAs) have been used as part of parenteral nutrition (PN) owing to their potential anti-inflammatory effects. The international lipids in PN Summit, encompassed discussions and the production of consensus guidelines concerning PN intravenous lipid emulsion (ILE) use in critical care. The Lipid Summit participants agreed that the inclusion of fish oil in ILEs is associated with meaningful clinical benefits without signals of harm, based on a strong biological rationale and current clinical evidence. Decisions concerning ILE choice should be made based on current evidence, thus addressing clinical requirements for guidance, particularly as further definitive evidence seems unlikely to occur. In addition, a future of individualized ICU care is envisioned, yielding better clinical outcomes. This approach will require the greater use of intelligent study designs incorporating the use of biomarkers of omega-3 derivatives, inflammatory-resolving processes, and/or muscle protein breakdown.

中文翻译：

---

含有 omega-3 脂肪酸的脂质乳剂对内科和外科重症监护患者的作用


在危重疾病中，炎症和氧化应激的调节可以改善患者的预后，因此 omega-3 多不饱和脂肪酸 （PUFA） 因其潜在的抗炎作用而被用作肠外营养 （PN） 的一部分。PN 峰会上的国际脂质包括关于在重症监护中使用 PN 静脉脂质乳剂 （ILE） 的讨论和共识指南的制定。脂质峰会与会者一致认为，根据强大的生物学原理和当前的临床证据，将鱼油纳入 ILE 与有意义的临床益处相关，没有危害信号。应根据当前证据做出有关 ILE 选择的决定，从而满足指导的临床要求，特别是当进一步明确的证据似乎不太可能出现时。此外，还设想了个体化 ICU 护理的未来，从而产生更好的临床结果。这种方法将需要更多地使用智能研究设计，包括使用 omega-3 衍生物、炎症分解过程和/或肌肉蛋白质分解的生物标志物。